TY - JOUR
T1 - Reporting on circulating tumor DNA monitoring in metastatic cancer
T2 - From clinical validity to clinical utility
AU - Brenner Thomsen, Caroline
AU - Dandanell Juul, Amanda
AU - Lefèvre, Anna Cecilie
AU - Glismand Truelsen, Christina
AU - Dizdarevic, Edina
AU - Ryssel, Heidi
AU - Mathilde Kjær, Ina
AU - Lycke Wind, Karen
AU - Callesen, Louise Bach
AU - Faaborg Larsen, Louise
AU - Støchkel Frank, Malene
AU - Fredslund Andersen, Rikke
AU - Garm Spindler, Karen Lise
AU - Jakobsen, Anders
N1 - Funding Information:
Anna Cecilie Lefèvre, Christina Glismand Truelsen, Karen Lycke Wind, Louise Bach Callesen, and Karen‐Lise Garm Spindler received financial support from The Research Foundation of The Central Denmark Region and The Danish Cancer Society.
PY - 2022/6
Y1 - 2022/6
N2 - This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.
AB - This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.
KW - circulating tumor DNA (ctDNA)
KW - clinical utility
KW - metastatic cancer
KW - monitoring
KW - reporting on circulating tumor DNA
KW - standardization
KW - Circulating Tumor DNA/genetics
KW - Neoplasms, Second Primary
KW - Humans
KW - Mutation
KW - Neoplasms/genetics
KW - Biomarkers, Tumor/genetics
U2 - 10.1002/cncr.34168
DO - 10.1002/cncr.34168
M3 - Comment/debate
C2 - 35302663
AN - SCOPUS:85126466118
SN - 0008-543X
VL - 128
SP - 2052
EP - 2057
JO - Cancer
JF - Cancer
IS - 11
ER -